insulin-like growth factor 1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Despite criticism and international opposition to his controversial anti-narcotics drive, Duterte's domestic approval rating remained relatively high throughout his presidency. Duterte began his presidency with a high trust rating of 79% and 91% (the highest of any Philippine official since 1999), from pollsters Social Weather Stations (SWS) and Pulse Asia, respectively. His net satisfaction rating reached its lowest at 45% in July 2018, attributed to inflation during the period as well as Duterte calling God "stupid" for the concept of original sin in the Bible; eventually, his satisfaction rating rose to 60% by the end of the year. Halfway through his term, Duterte's approval rating reached 79%, the highest among his predecessors at this stage in their presidencies. It rose to 87% by the end of 2019 due to the successful hosting of the 2019 Southeast Asian Games as well as the administration's poverty reduction programs. Amid the COVID-19 pandemic, Pulse Asia reported in September 2020 that 84% of Filipinos approved of the administration's efforts to contain the virus and provide assistance to those who lost their jobs; 92% of the poll respondents also agreed Duterte had "done well" in preventing the contagion in the country. Duterte ended 2021 with an approval rating of 60%, wherein higher net satisfaction was observed among those who have been or are willing to get vaccinated. Duterte maintained his high approval and trust ratings as he approached the end of his term.
=== Lost Connections (2018) === Lost Connections was published in the US and UK on January 23rd, 2018. In Lost Connections, Hari argues that depression and related mental health conditions are not solely caused by chemical imbalances in the brain, instead being rooted in social, environmental, and psychological factors. Hari emphasizes that someone who finds benefits in taking an anti-depressant medication should not stop taking them. Kirkus Reviews praised Lost Connections. In one of The Guardian's reviews of the book, arts writer Fiona Sturges alluded to Hari's earlier examples of journalism malpractice that date to his earlier period as a newspaper reporter. She noted that in contrast, Hari made notes and interview recordings for Lost Connection available. Lost Connections has been translated into German, Japanese, and Spanish. The original UK and US releases of Lost Connections have different subtitles. The full title of the UK edition reads: Lost Connections: Why You're Depressed and How to Find Hope, while the US edition reads: Lost Connections: Uncovering the Real Causes of Depression - and the Unexpected Solutions.
=== Fertility support === Progesterone is used for luteal support in assisted reproductive technology (ART) cycles such as in vitro fertilization (IVF). It is also used to correct luteal phase deficiency to prepare the endometrium for implantation in infertility therapy and is used to support early pregnancy.
=== Genetic instability === Considerable research has been funneled into the biological implications relating to the presence of H-DNA in the major breakpoint regions (Mbr) and double-strand-breakpoints of certain genes. Recent work has linked the presence of non-B-DNA structures with cases of genetic instability. Polypurine mirror-repeat H-DNA forming sequences were found neighboring the P1 promoter of the c-MYC gene and are associated with the major breakpoint hotspots of this region. Cases of genetic instability were also observed in the F1 offspring of transgenic mice after incorporation of human H-DNA-forming sequences paired with Z-DNA sequences into their genomes where no instability was previously reported. Additionally, formation of R.R.Y. H-DNA conformations have been observed at the Mbr of the bcl-2 gene. Formation of these structures has been posited to cause the t(14;18) translocation observed in many cancers and most follicular lymphomas. This observation has led to research that indicated a substantial decrease in translocation events can be observed after blocking the formation of H-DNA by altering the sequence of this region slightly. Long tracts of GAA·TTC have also been observed to form very stable H-DNA structures. Interactions between these two H-DNA structures, termed sticky DNA, has been shown to interrupt transcription of the X25, or frataxin gene. As decreased levels of the protein frataxin is associated with Friedreich's ataxia, formation of this instability has been suggested to be the basis for this genetic disease.
Sources: en.wikipedia.org
Benzo[a]pyrene is first oxidized by cytochrome P450 1A1 to form a variety of products, including (+)-benzo[a]pyrene-7,8-epoxide. This product is metabolized by epoxide hydrolase, opening up the epoxide ring to yield (−)-benzo[a]pyrene-7,8-dihydrodiol. The ultimate carcinogen is formed after another reaction with cytochrome P450 1A1 to yield the (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide. It is this diol epoxide that covalently binds to DNA. BaP induces cytochrome P450 1A1 (CYP1A1) by binding to the AHR (aryl hydrocarbon receptor) in the cytosol. Upon binding the transformed receptor translocates to the nucleus where it dimerises with ARNT (aryl hydrocarbon receptor nuclear translocator) and then binds xenobiotic response elements (XREs) in DNA located upstream of certain genes. This process increases transcription of certain genes, notably CYP1A1, followed by increased CYP1A1 protein production. This process is similar to induction of CYP1A1 by certain polychlorinated biphenyls and dioxins. Seemingly, CYP1A1 activity in the intestinal mucosa prevents major amounts of ingested benzo[a]pyrene to enter portal blood and systemic circulation. Intestinal, but not hepatic, expression of CYP1A1 depends on TOLL-like receptor 2 (TLR2), which is a eukaryotic receptor for bacterial surface structures such as lipoteichoic acid. Moreover, BaP has been found to activate a transposon, LINE1, in humans.
gametogenesis The process by which eukaryotic precursor germ cells divide and differentiate into haploid gametes. Depending on the organism, gametes may be generated from haploid germ cells by mitosis or diploid germ cells by meiosis.
2 HClO ⇌ Cl2O + H2O, K = 3.55 × 10−3 dm3/mol (at 0 °C) The presence of light or transition metal oxides of copper, nickel, or cobalt accelerates the exothermic decomposition into hydrochloric acid and oxygen:
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.